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ABSTRACT
There have been several studies evaluating the association between vitamin and mineral status and
menstrual disturbance. In the present study, we aimed to assess the relationship between the menstrual
bleeding pattern and premenstrual syndrome (PMS) symptoms with serum 25-hydroxyvitamin D, and
calcium levels in adolescent girls. A cross-sectional study was carried out in 897 high school girls from
northeastern Iran. The prevalence of hypocalcaemia, normal serum calcium and hypercalcaemia was
27.1, 59.8 and 13.1%, respectively. The menstrual flow of participants differed significantly between the
calcium status groups (p¼ .005). There was no significant association between the symptoms of PMS,
as assessed by the questionnaire and serum vitamin D status, or serum calcium concentrations, apart
from the irritability. There appears to be an association between serum calcium, menstrual blood loss
and irritability in adolescent girls.
IMPACT STATEMENT
 What is already known on this subject? Several studies have evaluated the association of vitamin
and mineral status with menstrual disturbance, although these relationships are not consistent, spe-
cifically among calcium and vitamin D levels with a menstrual bleeding pattern.
 What do the results of this study add? In the present study, we investigated the correlation of
menstrual bleeding patterns and PMS with calcium and vitamin D levels in a large population in
adolescent girls. We found that the level of calcium was associated with the level of menstrual
blood loss and irritability. However, no significant association was observed between the menstrual
bleeding pattern or the PMS symptoms with a vitamin D status.
 What are the implications of these findings for future clinical practise/research? Further studies
are required to assess the value of a calcium adequate intake or a calcium supplementation for the







Premenstrual symptoms, collectively often referred to as pre-
menstrual syndrome (PMS), and as dysmenorrhoea, are com-
mon gynaecological disorders affecting the quality of life and
performance of young women (Obeidat et al. 2012). PMS is
described as a cluster of disorders recognised by psycho-
logical and physical symptoms that occur during the luteal
phase of the menstrual cycle, that subside after the onset of
menses, and are related with some degree of inter-cycle vari-
ation (Freeman 2003). Young women often avoid consulting
a doctor about PMS, and consequently, it has a negative
effect on their physical and psychological welfare (Hickey and
Balen 2003).
There are several hypotheses about the aetiology of PMS,
including the possibility that some women are sensitive to
fluctuating hormone levels within the menstrual cycle
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(Halbreich et al. 2006), with an inadequate increase in proges-
terone levels during the early luteal phase being one
(Halbreich 2003). Several treatments have been suggested for
the PMS, although few have been demonstrated to be
effective.
Previous studies have reported a potential role of vitamin
and mineral status in the aetiology of PMS, and perhaps a
putative mechanism for the treatment of menstrual problems
(Proctor and Murphy 2001). It has been shown that the cal-
cium levels inside and outside cells may have effects on
neuromuscular junctions and the frequency of psychological
symptoms of PMS. Irritability, agitation and mania have been
reported in connection with low ionised calcium during the
first phase of menses (Thys-Jacobs et al. 2007).
The potential role of calcium has been studied previously,
and it has been reported that reduced calcium levels during
ovulation are related to the luteal phase of the cycle (Thys-
Jacobs and Alvir 1995; Bertone-Johnson et al. 2005). Serum
vitamin D has also been shown to fluctuate during the men-
strual cycle along with alterations in oestradiol at ovulation
and across the luteal phase in several, but not all of the stud-
ies (Thys-Jacobs 2000).
The vitamin D receptor is present in the reproductive tis-
sues (Evans et al. 2004; Lerchbaum and Obermayer-Pietsch
2012; Luk et al. 2012) and a low level of tissue vitamin D may
be related to several disturbances of the reproductive system,
such as early menarche (Luk et al. 2012) and uterine fibroids
(Baird et al. 2013). It has been reported that vitamin D
reduces the production of prostaglandins (Lasco et al. 2012).
The promoter region of the gene encoding the anti-M€ullerian
hormone (AMH) contains a vitamin D response element, sug-
gesting that vitamin D may regulate the expression of AMH
(Malloy et al. 2009). AMH, in turn, regulates the follicular
recruitment, which offers a mechanism for vitamin D to affect
ovarian function and the regularity of the menstrual cycle
(Luk et al. 2012).
Vitamin D deficiency is associated with infertility in rats
and mice (Lerchbaum and Obermayer-Pietsch 2012).
Knockout mice lacking the enzyme for producing the active
form of vitamin D show hypogonadism, oestrus cycle distur-
bances, arrested follicular development, lengthy oestrous
cycles, anovulation, and hypoplastic uteri (Panda et al. 2001;
Dicken et al. 2012).
The results of previous studies assessing the association
between PMS and vitamin D and calcium status have been
inconsistent. Thys-Jacobs et al. reported no significant differ-
ences in 25(OH)D, and 1,25(OH)2D between a woman with
premenstrual dysphoric disorder (PMDD) and their control
group (Thys-Jacobs et al. 2007). Vitamin D intake has been
reported to be inversely related to the prevalence of PMS
(Bertone-Johnson et al. 2010), although the serum 25(OH)D
concentrations were not related to the risk of PMS (Bertone-
Johnson et al. 2014). Because of the limited and inconsistent
data assessing the relationship between serum calcium and
vitamin D with the menstrual problems in young women, we
aimed to explore the relationship between the menstrual
bleeding patterns and PMS with calcium and vitamin D levels
in the adolescent girls living in northeastern Iran.
Materials and methods
Participants and setting
A cross-sectional study was conducted among high school
girls from the cities of Mashhad and Sabzevar in Iran, during
January 2015, as described previously (Bahrami et al. 2017,
2018; Tabatabaeizadeh et al. 2017). Participants were
recruited from different high schools in these two cities using
a randomised clustering method. The target population
included adolescent girls in these areas in the age group
12–18 years who had menarche for at least 1 year prior to
their time of recruitment. Written consent was obtained from
the students and their parents. Girls were excluded if they
were experiencing symptoms of untreated depression, history
of high blood pressure or dyslipidaemia, renal or liver disease,
cancer, or bone disease such as osteomalacia, malabsorption,
rheumatologic disease, thyroid disease, hyperparathyroidism,
multiple sclerosis, type 1 or type 2 diabetes, polycystic ova-
ries; or were taking specific drugs including corticosteroids,
anticonvulsants, anabolic steroids, propranolol, or cimetidine.
Of all of the 988 eligible students, 897 completed all the
requirements for the study. The study protocol was approved
by the Mashhad University of Medical Sciences.
Biochemical assessments
Ten millilitres of venous blood was obtained from each par-
ticipant after an overnight fast, irrespective of the phase of
the girls’ menstrual cycle. The blood samples were centri-
fuged and the sera were collected. Serum was assayed for
serum 25-hydroxyvitamin D [25(OH)D], calcium and albumin
concentrations. The vitamin D measurements were made
using an electrochemiluminescence method (Roche, Basel,
Switzerland) using Roche, Cobas, Germany kit and a vitamin
D status was categorised according to serum levels of
25(OH)D (Nesby-O’Dell et al. 2002; Gordon et al. 2004;
Misra et al. 2008; Kumar et al. 2009): vitamin D deficiency
15 ng/ml, and non-vitamin D deficiency >15 ng/ml.
The serum concentrations of calcium and albumin were
assessed using Pars Azmoon kits (Tehran, Iran), in accordance
with the instructions provided. Albumin-corrected calcium
was calculated using the following formulae (Sava et al. 2005):
Corrected total calcium ðmg=dlÞ :

½4 albumin ðg=lÞ  0:8

þ total serum calcium ðmg=dlÞ
Corrected total calcium ðmmol=lÞ
¼ Corrected total calcium ðmg=dlÞ  0:25:
Albumin-corrected calcium status was categorised into
three groups according to serum levels: hypocalcaemia
2.17mmol/l, normal serum calcium 2.17–2.47mmol/l and
hypercalcaemia 2.47mmol/l (Gøransson et al. 2005).
Evaluation of menstrual pattern and premenstrual
syndrome
In this study, the girls completed a questionnaire
comprising questions about their menstrual cycle and PMS.
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The questionnaire was self-administered or, with the aid of
an expert nurse. The menstrual pattern variables included in
the questionnaire were: their age at menarche, the presence
of dysmenorrhoea, the average days of bleeding (short bleed-
ing times of <4 d, normal times of 4–6 d, long times of >6 d),
the duration of their latest menstruation intervals (>21,
21–35, > 35 d), and self-reported blood loss per cycle (as little,
moderate, and heavy).
The girls were also asked to answer 16 items that
described the symptoms and signs of PMS: the physical
symptoms (abdominal pain, backache, foot pain, vomiting,
nausea, and diarrhoea), any psychological and behavioural
symptoms (appetite changes, irritability, fatigue, palpitation,
lack of energy, sleep pattern changes, depression and sad-
ness, decrease of interest, loss of concentration, and tendency
to cry easily) and the severity of each symptom. The girls
who had at least two symptoms, one physical and one psy-
chological symptom were considered as having PMS, while
those with just one symptom or no symptoms were regarded
as Non-PMS (Mortola et al. 1990). The pain severity was rated
as mild, severe and very severe.
Measurement of covariates
The demographic and anthropometric information including
age, height, weight and waist circumference were obtained
in health centres, by a trained paramedic. Body mass index
(BMI) was calculated as weight (kilograms) divided by height
(metres) squared. The physical activity was evaluated through
a validated questionnaire and classified as metabolic equiva-
lents (METs) in hours/day (Delshad et al. 2015). To measure
smoking exposure, we asked about time of exposure during
a day.
Statistical analysis
IBM SPSS Statistics 18.0 for Windows (SPSS Inc., Chicago, IL)
was used for all of the statistical analyses. The
Kolmogorov–Smirnov test was used to examine a normal dis-
tribution of variables. The categorical variables were
expressed as a number (percentage) and quantitative varia-
bles as the mean± SD or median (interquartile range [IQR]),
as suitable. The categorical data were compared using the
v2 test. The Student’s t-test or ANOVA were used, as appro-
priate, to compare quantitative variables. Followed by
ANOVA, Tukey HSD post hoc tests were conducted. p< .05
was considered statistically significant. A logistic regression
analysis was applied to calculate the risk of PMS according to
the calcium and vitamin D levels and as continuous or a cat-
egorical variable.
Results
Descriptive characteristics of the study population
The demographics, anthropometric, biochemical and lifestyle
data of the participants are summarised in Table 1. The ages
of the participants ranged from 12 to 18 in years with a
mean age of 14.72 (±1.5) years. The mean BMI was
21.45 ± 4.2 kg/m2 and girls averaged 45.29 ± 3.4 MET-hours
per day of physical activity. 20.6% of participants disclosed
aspects of smoking exposure. 85.3% of all participants had a
vitamin D deficiency and 27.1% had corrected serum calcium
below the reference range and 13.1% of them had corrected
serum calcium levels above the reference range.
The characteristics of the menstrual cycle including cycle
length, duration of flow, and amount of flow are reported in
Table 2. The mean age at menarche of our study population
was 12.61 ± 1.1 years. The most frequently observed men-
strual cycle length was 21–35 d, with the most common men-
strual bleeding length being 4–7 d. PMS (47.3%) was a
common menstrual cycle disorder among the subjects in this
study. Of whom, 37.3% required analgesic medicine for relief
of symptoms.
The most common physical symptom was an abdominal
pain (657 girls, 73.2%) and backache (537 girls, 59.9%). The
most prevalent psychological and behavioural symptoms were
an increased tendency to cry easily (292 girls, 32.5%), and a
loss of concentration (259 girls, 28.9%) (Tables 3 and 4).
Relationship between calcium levels, menstrual bleeding
pattern and PMS
The mean albumin-corrected calcium level was 2.26mmol/l
(standard deviation: 0.2), with a median of 2.27mmol/l (IQR:
2.16, 2.37mmol/l). Two hundred and forty-three of the 897
girls (27.1%) had low corrected serum calcium, 536 (59.8%)
had normal-corrected serum calcium level, and 118 (13.1%)
had a high, corrected serum level of calcium.
No significant differences were found for BMI, height,
weight, smoking exposure or physical activity between the
Table 1. Relationship of characteristics of participants to serum calcium and vitamin D concentrations.
Variable











Number of subject 765 (85.3%) 132 (14.7%) 243 (27.1) 536 (59.8) 118 (13.1)
Age (year) 14.63 ± 1.49 15.03 ± 1.51 .009a 14.62 ± 1.52 15.0 ± 1.42 14.25 ± 1.32 <.001c,d
BMI (kg/m2) 21.60 ± 4.36 21.31 ± 4.23 NSa 21.52 ± 4.10 21.59 ± 4.13 21.61 ± 3.50 NSc
Waist circumference (cm) 71.19 ± 9.27 69.65 ± 7.28 NSa 70.54 ± 8.05 71.25 ± 8.92 72.67 ± 7.78 NSc
Passive smoking exposure, n (%) 163 (21.3) 22 (16.7) NSb 63 (25.8) 105 (19.6) 17 (14.7) NSb
Data presented as numbers and per cent within parenthesis, mean ± SD as appropriate.
aStatistical significance assessed using the t-test.
bStatistical significance assessed using the v2 test.
cStatistical significance assessed using the ANOVA test.
dSignificant between 1, 2 and 2, 3 groups.
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three calcium categories but the mean age was higher in nor-
mal calcium group compared to the other two groups.
There were no significant differences between the groups
with regard to age at menarche, menstrual bleeding length,
menstrual cycle length, and PMS. But, the menstrual flow of
participants differed significantly from the calcium status
groups (p¼ .005).
The incidence of physical symptom of PMS was similar in
the three groups, and there were no significant differences
observed between the groups.
The frequency of the most common psychological symp-
tom did not differ significantly between the groups compared
to other two groups (p> .05). But, the prevalence of irritabil-
ity was significantly higher in the hypercalcaemia and
Table 2. Relation of menstrual pattern to calcium and vitamin D level.
Variable











Age at menarche (year), mean ± SD 12.46 ± 1.34 12.57 ± 1.12 NSa 12.40 ± 1.10 12.52 ± 1.45 12.48 ± 1.02 NSc
Average days of bleeding, n (%)
Short bleeding periods (4 d) 37 (4.8) 7 (5.3) NSb 16 (6.6) 24 (4.4) 4 (3.4) NSb
Normal periods (4–7 d) 617 (80.6) 110 (83.3) 191 (78.6) 448 (83.6) 88 (74.6)
Long periods (>7 d) 111 (14.6) 15 (11.4) 36 (14.8) 64 (11.6) 26 (31.0) (22.0)
Duration of the menstruation cycle, n (%)
21 d 170 (22.2) 23 (17.6) NSb 54 (22.2) 99 (18.5) 40 (33.9) NSb
21–35 d 555 (72.6) 106 (80.2) 176 (72.4) 407 (75.9) 78 (66.1)
35 d 40 (5.2) 3 (2.2) 13 (5.4) 30 (5.6) 0 (0)
Menstrual flow, n (%)
Little 196 (25.6) 25 (18.9) NSb 84 (34.5) 124 (23.2) 13 (10.9) .005b
Moderate 559 (73.0) 101 (76.5) 154 (63.2) 405 (75.5) 101 (85.9)
Heavy 10 (1.4) 6 (4.4) 5 (2.3) 7 (1.3) 4 (3.2)
PMS
Yes 359 (46.9) 65 (49.2) NSb 115 (47.3) 249 (46.4) 60 (45.5) NSb
No 406 (53.1) 67 (50.8) 128 (52.7) 259 (53.6) 58 (54.5)
Use of medication, n (%)
Yes 293 (37.2) 42 (29.6) NSb 107 (44.1) 182 (34.0) 46 (39.1) NSb
No 472 (62.8) 90 (70.4) 136 (55.9) 354 (66.0) 72 (60.9)
Classification of pain, n (%)
Painless 46 (6.0) 11 (8.3) NSb 20 (8.4) 32 (6.0) 5 (4.3) NSb
Mild 351 (45.8) 62 (47.0) 90 (37.1) 272 (50.8) 51 (43.5)
Moderate 189 (24.6) 25 (18.9) 68 (28.0) 110 (20.6) 36 (30.5)
Severe 179 (23.6) 34 (25.8) 65 (26.5) 122 (22.6) 26 (21.7)
Data presented as numbers and per cent within parenthesis and meanþ SD as appropriate.
Significance of bold values is p value <.05.
aStatistical significance assessed using the t-test.
bStatistical significance assessed using the v2 test.
cStatistical significance assessed using the ANOVA test.
Table 3. Relation of physical symptoms of premenstrual syndrome (PMS) to calcium and vitamin D level.
Physical symptoms












Yes 561 (73.3) 96 (72.7) NS 172 (70.6) 394 (73.7) 91 (76.8) NS
No 204 (26.7) 36 (27.3) 71 (29.4) 142 (26.3) 27 (23.2)
Foot pain
Yes 167 (21.8) 31 (23.4) NS 53 (21.7) 116 (21.6) 29 (24.6) NS
No 598 (78.2) 102 (76.6) 190 (78.3) 420 (78.4) 89 (75.4)
Backache
Yes 475 (62.9) 80 (62.6) NS 146 (60.1) 330 (61.6) 79 (66.7) NS
No 290 (37.1) 52 (37.4) 97 (39.9) 206 (38.4) 39 (33.3)
Nausea
Yes 60 (7.9) 12 (9.6) NS 27 (11.2) 42 (7.9) 3 (2.9) NS
No 705 (92.1) 60 (90.4) 216 (88.8) 494 (92.1) 115 (97.1)
Vomiting
Yes 19 (2.5) 6 (4.5) NS 12 (4.9) 10 (1.9) 3 (2.9) NS
No 746 (97.5) 127 (95.5) 231 (95.1) 526 (98.1) 115 (97.1)
Diarrhoea
Yes 25 (3.2) 6 (4.5) NS 12 (4.9) 17 (3.2) 2 (1.4) NS
No 740 (96.8) 127 (97.5) 231 (95.1) 519 (96.8) 116 (98.6)
Data presented as numbers and per cent within parenthesis.
Statistical significance assessed using the v2 test.
4 A. BAHRAMI ET AL.
hypocalcaemia groups compared to the normal calcium level
group (p¼ .018).
Relationship between serum 25OHD level, menstrual
bleeding pattern and PMS
The mean serum 25(OH)D concentration was 9.41 ng/ml
(standard deviation: 8.9), with a median of 6.8 ng/ml (IQR: 4.0,
10.1 ng/ml). Most of the girls [85.3% (n¼ 755)] had a serum
vitamin D concentration 25(OH)D level below 15 ng/ml and
14.7% (n¼ 132) had a serum vitamin D concentrations
25(OH)D level above 15 ng/ml.
No differences were found in the BMI, height, weight,
smoking exposure or physical activity between the two vita-
min D categories, but the mean age of the participants was
slightly higher in the non-deficient group (Table 1). The vita-
min D deficient and non-vitamin D deficient cases did not dif-
fer significantly with respect to menstrual disorders and PMS
(Tables 2 and 3).
There were no statistically significant differences in the
prevalence of physical, psychological and behavioural symp-
toms of PMS between the vitamin D deficient and vitamin D
non-deficient groups (Tables 3 and 4). Moreover, serum
25(OH)D and albumin-corrected calcium levels could not pre-
dict the risk of PMS, whether it was a continuous variable or
as a categorical variable (Table 5).
Discussion
PMS was a common finding in our study subjects, and this
has been reported to be a frequent menstrual problem in
other populations (Bertone-Johnson et al. 2005; Obeidat et al.
2012; Konapur and Nagaraj 2014). Our cross-sectional study
suggests that high corrected serum calcium may have a sig-
nificant association on the incidence of irritability. The study
of Kia et al. showed that the low serum levels of calcium
though, within the reference range, was in the PMS partici-
pants compared to the healthy controls (Kia et al. 2015).
Furthermore, a daily consumption of calcium carbonate
reduced the severity of the PMS symptoms versus the placebo
(48% vs. 30%) (Thys-Jacobs et al. 1998). Bendich and Bertone-
Johnson also demonstrated a positive effect of calcium admin-
istrations on improving PMS symptoms (Bendich 2000;
Table 4. Relation of psychological symptoms of premenstrual syndrome (PMS) to calcium and vitamin D level.













Yes 3 (0.4) 0 (0) NS 3 (1.4) 0 (0) 0 (0) NS
No 762 (99.6) 132 (100) 240 (98.6) 536 (100) 118 (100)
Irritability
Yes 51 (6.7) 4 (2.3) NS 16 (6.4) 23 (4.2) 16 (13.2) .018
No 714 (93.3) 128 (97.7) 227 (93.6) 513 (95.8) 102 (86.8)
Fatigue
Yes 70 (9.2) 11 (10.0) NS 19 (7.8) 45 (8.4) 17 (14.7) NS
No 695 (90.8) 121 (90.0) 224 (92.2) 491 (91.6) 101 (85.3)
Palpitation
Yes 70 (9.2) 13 (10.0) NS 21 (8.5) 50 (9.3) 12 (10.3) NS
No 695 (90.8) 119 (90.0) 222 (91.5) 486 (90.7) 106 (90.8)
Lack of energy
Yes 85 (11.1) 15 (11.4) NS 33 (13.5) 48 (9.0) 19 (16.2) NS
No 680 (88.9) 117 (89.6) 210 (86.5) 488 (91.0) 99 (83.8)
Sleep pattern changes
Yes 4 (0.5) 0 (0) NS 4 (1.5) 0 (0) 0 (0) NS
No 761 (99.5) 132 (100) 239 (98.5) 536 (100) 118 (100)
Depression and sadness
Yes 68 (8.9) 14 (10.6) NS 29 (11.9) 44 (8.3) 9 (7.4) NS
No 697 (91.1) 118 (89.4) 214 (88.1) 492 (91.7) 109 (92.6)
Decrease interest
Yes 100 (13.1) 16 (12.2) NS 33 (13.5) 60 (11.2) 23 (19.4) NS
No 665 (86.9) 116 (87.8) 210 (86.5) 476 (88.8) 95 (80.6)
Loss of concentration
Yes 223 (29.1) 36 (27.2) NS 76 (31.1) 156 (29.1) 27 (22.5) NS
No 542 (70.9) 96 (72.8) 167 (68.9) 380 (70.9) 91 (77.5)
Tendency to cry easily
Yes 252 (32.9) 40 (30.3) NS 80 (33.1) 167 (31.1) 45 (38.2) NS
No 513 (67.1) 92 (69.7) 163 (66.9) 369 (68.9) 73 (61.8)
Data presented as numbers and per cent within parenthesis.
Significance of bold values is p value <.05.
Statistical significance assessed using the v2 test.
Table 5. Logistic regression analysis of serum vitamin D and calcium as a pre-
dictor of premenstrual syndrome (PMS), using different groups of vitamin D
and calcium.
OR CI p value
25(OH)D as continuous variable 0.996 0.981–1.011 .578
25(OH)D as categorical variable
25(OH)D 15 ng/ml ref – –
25(OH)D> 15 ng/ml 0.955 0.644–1.418 .821
Corrected calcium as continuous variable 0.736 0.312–1.734 .492
Corrected calcium as categorical variable
Calcium 2.17mmol/l ref – –
2.17mmol/l< Calcium <2.47mmol/l 1.318 0.740–2.350 .349
Calcium 2.47mmol/l 1.394 0.825–2.356 .215
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Bertone-Johnson et al. 2005). We also found that in the
hypercalcaemia group, the majority of the participants pre-
sented moderate blood flow. The amount of blood loss dur-
ing menstruation affects the overall quality of life of women
(Davies and Kadir 2017), so, this may be clinically relevant.
There was a high prevalence of vitamin D deficiency in
our population sample of healthy girls. However, the preva-
lence of PMS symptoms did not differ significantly in relation-
ship to vitamin D status. Another study in Iran showed that
there was no significant difference in vitamin D serum status
between PMS and control groups (Kia et al. 2015). Thys-
Jacobs and a co-researcher reported that serum 25(OH)D lev-
els were significantly lower in PMS cases through three
phases of the menstrual cycle, while 1,25(OH)2D levels were
not significantly higher in PMS cases at all phases of the
menstrual cycle (Thys-Jacobs and Alvir 1995). In a further
study, 25(OH)D levels were non-significantly lower in women
with PMDD compared to healthy controls (Thys-Jacobs et al.
2007). Furthermore, Obeidat et al. reported that PMS has no
relationship to levels of parathyroid hormone, vitamin D or
dairy products consumption in dysmenorrheic college stu-
dents (Obeidat et al. 2012). Jukic et al found lower plasma
levels of 25(OH)D were linked with irregular cycles, but not
with short or long cycles (Jukic et al. 2015). This discrepancy
with our result may be due to the different population sam-
ples; cycle regularity may be varying between younger and
older women.
Our results are also consistent with results from a previous
longitudinal study conducted between 1991 and 2005 that
showed that women with PMS did not differ with respect to
plasma levels of 25(OH)D, total calcium or parathyroid hor-
mone, compared to their matched normal controls (Bertone-
Johnson et al. 2014).
The strengths of our study include a comprehensive
assessment of the aspect of menstrual bleeding pattern in a
large population sample. Despite the large sample size, there
were several limitations. The cross-sectional nature of our
study does not allow the inference of causality. Recall bias
may be another potential problem, due to the use of a self-
administered questionnaire. All results were based on self-
reported symptoms, and most of the adolescent in this study
had 25(OH)D deficiency which reduced the power of the
study to detect any association between the dichotomous
25(OH)D exposure (15 ng/ml vs. >15 ng/ml) and menstrual
problems.
Conclusion
Menstrual disorders and PMS are common in adolescent girls.
The results from this study show no relationship between
serum vitamin D levels and PMS. Whilst corrected serum cal-
cium was associated with menstrual blood loss and irritability,
and would support the benefits of an adequate intake of
vitamin D; this needs to be assessed by an intervention study.
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